Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
NCT ID: NCT00059644
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
560 participants
INTERVENTIONAL
2001-07-31
2004-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
NCT00059657
Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease
NCT00053716
Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease
NCT02194686
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
NCT01131013
Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)
NCT01952756
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ecraprost in lipid emulsion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject has exhausted all standard revascularization treatment options at this time.
Exclusion Criteria
* Subjects with end stage renal disease (ESRD) defined as significant renal dysfunction evidenced by estimated creatinine clearance of \< 20 cc/min, or receiving chronic hemodialysis therapy.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mitsubishi Tanabe Pharma Corporation
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Tucson, Arizona, United States
Glendale, California, United States
Los Angeles, California, United States
Pasadena, California, United States
San Francisco, California, United States
Pensacola, Florida, United States
Springfield, Illinois, United States
Indianapolis, Indiana, United States
New Orleans, Louisiana, United States
Royal Oak, Michigan, United States
Biloxi, Mississippi, United States
Kansas City, Missouri, United States
Henderson, Nevada, United States
West Caldwell, New Jersey, United States
New York, New York, United States
Charlotte, North Carolina, United States
Portland, Oregon, United States
San Antonio, Texas, United States
Tacoma, Washington, United States
Birmingham, , United Kingdom
Bristol, , United Kingdom
Dundee, , United Kingdom
Hull, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Southhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WFI 01-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.